The nuclear receptor ligand-binding domain: structure and function.

[1]  William Bourguet,et al.  A canonical structure for the ligand-binding domain of nuclear receptors , 1996, Nature Structural Biology.

[2]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[3]  H. Gronemeyer,et al.  How to finger DNA , 1995, Nature.

[4]  A. Wolffe,et al.  Acetylation of general transcription factors by histone acetyltransferases , 1997, Current Biology.

[5]  Christopher K. Glass,et al.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.

[6]  H. Gronemeyer,et al.  Transcription factors 3: nuclear receptors. , 1995, Protein profile.

[7]  M. Stallcup,et al.  Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. , 1998, Molecular Endocrinology.

[8]  E. Kalkhoven,et al.  AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.

[9]  H. Gronemeyer,et al.  The coactivator TIF2 contains three nuclear receptor‐binding motifs and mediates transactivation through CBP binding‐dependent and ‐independent pathways , 1998, The EMBO journal.

[10]  P. Chambon,et al.  Conformational adaptation of agonists to the human nuclear receptor RARγ , 1998, Nature Structural Biology.

[11]  A. Wolffe.  Transcriptional control. Sinful repression. , 1997, Nature.

[12]  F. Jeanmougin,et al.  A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. , 1996, The EMBO journal.

[13]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[14]  C. Glass,et al.  Nuclear receptor coactivators. , 2000, Advances in pharmacology.

[15]  H. Gronemeyer,et al.  Nuclear receptors. How to finger DNA. , 1995, Nature.

[16]  J. Lehmann,et al.  An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.

[17]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[18]  A. Stewart,et al.  Different positioning of the ligand‐binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists , 1998, The EMBO journal.

[19]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[20]  Miguel Beato,et al.  Steroid hormone receptors: Many Actors in search of a plot , 1995, Cell.

[21]  J. Chen,et al.  RAC 3 , a steroid y nuclear receptor-associated coactivator that is related to SRC-1 and TIF 2 , 1997 .

[22]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[23]  P. Chambon,et al.  Ligand- and DNA-induced dissociation of RXR tetramers. , 1998, Journal of molecular biology.

[24]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[25]  Philippe Kastner,et al.  Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life? , 1995, Cell.

[26]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[27]  Jeffrey A. Lefstin,et al.  Allosteric effects of DNA on transcriptional regulators , 1998, Nature.

[28]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[29]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[30]  Bruce M. Spiegelman,et al.  Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ , 1996, Science.

[31]  P. Chambon,et al.  Stimulation of RARα Activation Function AF-1 through Binding to the General Transcription Factor TFIIH and Phosphorylation by CDK7 , 1997, Cell.

[32]  E. Kalkhoven,et al.  Isoforms of steroid receptor co‐activator 1 differ in their ability to potentiate transcription by the oestrogen receptor , 1998, The EMBO journal.

[33]  N. Koibuchi,et al.  TRAM-1, A Novel 160-kDa Thyroid Hormone Receptor Activator Molecule, Exhibits Distinct Properties from Steroid Receptor Coactivator-1* , 1997, The Journal of Biological Chemistry.

[34]  E. Baulieu,et al.  Steroid hormone receptors. , 1975, Vitamins and hormones.

[35]  P. Chambon,et al.  Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex , 1990, Cell.

[36]  B. Katzenellenbogen,et al.  Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. , 1996, Molecular endocrinology.

[37]  S. Yeh,et al.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[39]  Hui Li,et al.  RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. Yamamoto,et al.  Intracellular receptors use a common mechanism to interpret signaling information at response elements. , 1996, Genes & development.

[41]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[42]  M. Pazin,et al.  What's Up and Down with Histone Deacetylation and Transcription? , 1997, Cell.

[43]  C. Hänni,et al.  Ligand binding was acquired during evolution of nuclear receptors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Wolffe,et al.  Determinants of chromatin disruption and transcriptional regulation instigated by the thyroid hormone receptor: hormone‐regulated chromatin disruption is not sufficient for transcriptional activation , 1997, The EMBO journal.

[45]  E. Kalkhoven,et al.  Ligand‐independent activation of the oestrogen receptor by mutation of a conserved tyrosine , 1997, The EMBO journal.

[46]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[47]  H. Gronemeyer,et al.  Sequences in the ligand-binding domains of the human androgen and progesterone receptors which determine their distinct ligand identities. , 1997, Journal of molecular endocrinology.

[48]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.

[49]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.

[50]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[51]  P. Chambon,et al.  A mutation mimicking ligand‐induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers , 1997, The EMBO journal.